Lonza Group AG / Key word (s): Quarter Results Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024 24-Oct-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR ...

Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced today a long-term extension of its collaboration with a major global biopharmaceutical partner ...

The acquisition of the large-scale mammalian manufacturing site complements Lonza’s ongoing investments in large-scale bioconjugation in Visp (CH) and drug product manufacturing in Stein (CH), ...

Figures prepared in accordance with International Accounting Standards. Market value as of Oct. 23, 2023. © 2024 Fortune Media IP Limited. All Rights Reserved. Use ...

Swiss biotech firm Lonza will add three more production lines to its site in Visp, southwestern Switzerland, to manufacture an active ingredient for the Moderna vaccine, as part of a larger effort ...

The Lonza plant at Visp, deep in the Swiss Alps, is a hive of activity. Workers are racing to set up production lines to be able to start making a Covid-19 vaccine for US firm Moderna later this year.